[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20055417D0 - Farmasoytisk blanding inneholdene histon-deacetylaseinhibitor - Google Patents

Farmasoytisk blanding inneholdene histon-deacetylaseinhibitor

Info

Publication number
NO20055417D0
NO20055417D0 NO20055417A NO20055417A NO20055417D0 NO 20055417 D0 NO20055417 D0 NO 20055417D0 NO 20055417 A NO20055417 A NO 20055417A NO 20055417 A NO20055417 A NO 20055417A NO 20055417 D0 NO20055417 D0 NO 20055417D0
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
composition containing
histone deacetylase
deacetylase inhibitor
containing histone
Prior art date
Application number
NO20055417A
Other languages
English (en)
Other versions
NO20055417L (no
Inventor
Osamu Nakanishi
Tatsuo Sugawara
Hideyuki Migita
Yasuhiro Matsuba
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20055417D0 publication Critical patent/NO20055417D0/no
Publication of NO20055417L publication Critical patent/NO20055417L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20055417A 2003-05-26 2005-11-16 Farmasoytisk blanding inneholdene histon-deacetylaseinhibitor NO20055417L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003148073 2003-05-26
PCT/JP2004/007562 WO2004103369A1 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor

Publications (2)

Publication Number Publication Date
NO20055417D0 true NO20055417D0 (no) 2005-11-16
NO20055417L NO20055417L (no) 2005-12-19

Family

ID=33475383

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055417A NO20055417L (no) 2003-05-26 2005-11-16 Farmasoytisk blanding inneholdene histon-deacetylaseinhibitor

Country Status (27)

Country Link
US (1) US20070098816A1 (no)
EP (1) EP1626719A1 (no)
JP (1) JP2006526031A (no)
KR (1) KR100938712B1 (no)
CN (2) CN1794991A (no)
AR (1) AR045318A1 (no)
AU (1) AU2004241873C1 (no)
BR (1) BRPI0410959A (no)
CA (4) CA2527191A1 (no)
CL (1) CL2004001278A1 (no)
CO (1) CO5660262A2 (no)
CR (1) CR8163A (no)
CU (1) CU23490B7 (no)
EC (1) ECSP056253A (no)
IL (1) IL171941A0 (no)
ME (1) MEP32308A (no)
MX (1) MXPA05012345A (no)
NO (1) NO20055417L (no)
NZ (1) NZ543591A (no)
PE (1) PE20050206A1 (no)
RS (1) RS20050884A (no)
RU (1) RU2322971C2 (no)
TW (1) TW200505424A (no)
UA (1) UA81499C2 (no)
UY (1) UY28330A1 (no)
WO (1) WO2004103369A1 (no)
ZA (1) ZA200509515B (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
SI2263694T1 (sl) 2003-09-25 2013-09-30 Astellas Pharma Inc. Antitumorsko sredstvo, ki obsega inhibitor histon-deacetilaze FK228 in inhibitor topoizomeraze II doksorubicin
US7446126B2 (en) * 2004-10-08 2008-11-04 Indena S.P.A. Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel
EP1712552A1 (en) * 2005-04-11 2006-10-18 INDENA S.p.A. Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel
KR20150008926A (ko) * 2005-03-11 2015-01-23 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 암 세포를 표피 성장 인자 억제제에 대해 감작화시키는 히스톤 데아세틸라제 억제제
CA2601706C (en) 2005-03-22 2016-09-20 Dana-Farber Cancer Institute, Inc. Treatment of protein degradation disorders
BRPI0613429A2 (pt) 2005-07-14 2009-02-10 Takeda San Diego Inc inibidores de histona desacetilase
WO2008091349A1 (en) 2006-02-14 2008-07-31 The President And Fellows Of Harvard College Bifunctional histone deacetylase inhibitors
BRPI0707826B1 (pt) 2006-02-14 2022-04-19 Dana-Farber Cancer Institute, Inc. Compostos inibidores de histona desacetilase, composição farmacêutica e uso dos referidos compostos
CA2654540C (en) 2006-05-03 2017-01-17 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
CA2674084C (en) 2006-12-26 2013-05-14 Pharmacyclics, Inc. Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
CA2709383A1 (en) * 2007-12-14 2009-06-25 Milton L. Brown Histone deacetylase inhibitors
WO2010011296A2 (en) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
AU2009286982C1 (en) * 2008-08-29 2012-04-26 Bayer Intellectual Property Gmbh N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275)polymorph B
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
KR101755216B1 (ko) 2008-12-19 2017-07-07 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 피라진 유도체
US20120034302A1 (en) * 2009-02-11 2012-02-09 Liangping Yu Particulate composition and the method of making the same
CN102573826A (zh) * 2009-05-01 2012-07-11 奥克兹美制药公司 用于治疗癌症的喷他脒组合
AU2010259035A1 (en) * 2009-06-08 2011-12-08 Gilead Sciences, Inc. Alkanoylamino benzamide aniline HDAC inhibitor compounds
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
PL2470173T3 (pl) * 2009-08-25 2016-11-30 Leczenie skojarzone nanocząstkowymi kompozycjami taksanu i inhibitorów hedgehog
RU2012153675A (ru) 2010-05-12 2014-06-20 Вертекс Фармасьютикалз Инкорпорейтед Соединения, пригодные в качестве ингибиторов atr киназы
UA110853C2 (uk) 2011-09-13 2016-02-25 Фармасайклікс, Інк. Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
IN2014CN02501A (no) * 2011-09-30 2015-06-26 Vertex Pharma
KR102013133B1 (ko) 2011-09-30 2019-08-22 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물의 제조 방법
WO2013085902A1 (en) * 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
CA2869309C (en) 2012-04-05 2021-02-09 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
WO2014055756A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
JP6320506B2 (ja) 2013-03-12 2018-05-09 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
WO2014141129A2 (en) * 2013-03-14 2014-09-18 Grueneberg Dorre A Novel methods, compounds, and compositions for inhibition of ros
WO2015127227A1 (en) * 2014-02-21 2015-08-27 Cleveland Biolabs, Inc. Uses of flagellin for improved chemotherapy
WO2016044138A1 (en) 2014-09-17 2016-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
JP3354090B2 (ja) 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
CN1319009A (zh) * 1998-09-25 2001-10-24 沃尼尔·朗伯公司 乙酰地那林与吉西他滨、卡帕西滨或顺铂组合化疗癌症
JP4509395B2 (ja) * 1999-04-27 2010-07-21 田辺三菱製薬株式会社 肝臓疾患の予防治療薬
PL355170A1 (en) * 1999-11-10 2004-04-05 Warner-Lambert Company Combination chemotherapy
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
JP2003137866A (ja) * 2001-11-01 2003-05-14 Sankyo Co Ltd フェニレンジアミン誘導体

Also Published As

Publication number Publication date
CL2004001278A1 (es) 2005-05-06
NO20055417L (no) 2005-12-19
KR20060009371A (ko) 2006-01-31
CN101322707A (zh) 2008-12-17
CR8163A (es) 2006-07-14
KR100938712B1 (ko) 2010-01-25
AU2004241873B2 (en) 2008-05-08
AU2004241873A1 (en) 2004-12-02
CA2634766A1 (en) 2004-12-02
NZ543591A (en) 2009-09-25
CA2634709A1 (en) 2004-12-02
CU23490B7 (es) 2010-02-23
RU2322971C2 (ru) 2008-04-27
RS20050884A (en) 2008-04-04
EP1626719A1 (en) 2006-02-22
CA2634765A1 (en) 2004-12-02
IL171941A0 (en) 2006-04-10
TW200505424A (en) 2005-02-16
CO5660262A2 (es) 2006-07-31
CA2527191A1 (en) 2004-12-02
RU2005140570A (ru) 2006-06-10
AU2004241873C1 (en) 2009-01-22
AU2004241873B8 (en) 2008-05-29
MEP32308A (en) 2010-10-10
PE20050206A1 (es) 2005-03-26
CN1794991A (zh) 2006-06-28
BRPI0410959A (pt) 2006-07-04
US20070098816A1 (en) 2007-05-03
JP2006526031A (ja) 2006-11-16
WO2004103369A1 (en) 2004-12-02
UY28330A1 (es) 2004-12-31
ZA200509515B (en) 2006-07-26
ECSP056253A (es) 2006-10-25
MXPA05012345A (es) 2006-02-08
AR045318A1 (es) 2005-10-26
UA81499C2 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
NO20055417D0 (no) Farmasoytisk blanding inneholdene histon-deacetylaseinhibitor
ATE473005T1 (de) Histone-deacetylase-inhibitoren
ATE354366T1 (de) Histondeacetylase-hemmer
DK1495002T3 (da) Benzamide derivatives useful as histone deacetylase inhibitors
ATE395343T1 (de) Sulfonylderivate als histone-deacetylase- inhibitoren
PL378181A1 (pl) Pochodne kwasu hydroksamidowego jako inhibitory deacetylazy histonowej (HDAC)
HK1080465A1 (zh) 作為組蛋白脫乙酰酶新穎抑制劑的磺酰基氨基衍生物
PL374970A1 (en) Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors
IS7714A (is) Lyfjasamsetningar úr módafíníl
DK1354873T3 (da) Perindoaprilsalt og farmaceutiske sammensætninger indeholdende dette
AU2003286249A8 (en) Histone deacetylase inhibitors
IS7715A (is) Nýjar lyfjasamsetningar úr módafíníl
EP1408946A4 (en) HISTONE DEACETYLASE INHIBITORS
NO20032183D0 (no) Histon-deacetylase inhibitor og anvendelse derav
NO20044164L (no) Farmasoytiske sammensetninger
PT1467737E (pt) Composicao farmaceutica orodispersivel de piribedil
TWI346661B (en) Inhibitors of histone deacetylase
DK1301184T3 (da) Valproinsyre og derivater deraf som histondeacetylaseinhibitorer
ITMI20030705A1 (it) Composizione farmaceutica contenente n-acetil-l-cisteina
DOP2002000508A (es) Composición farmaceutica
ITFI20050240A1 (it) Aril ossadiazoli inibitori dell'istone deacelitasi e formulazioni farmaceutiche che li contengono
ITMI20020926A1 (it) Composizioni farmaceutiche riepitelizzanti

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application